文献速递前列腺癌

IsoPSA™ 单参数结构基础检测法用于提高高级别前列腺癌检出率的临床验证

Clinical Validation of IsoPSA™, a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer.
PubMed 文献 · J Urol · 2019-01-01

本研究为多中心前瞻性验证,纳入2017年5月至2018年3月在7个学术与社区中心计划接受前列腺活检的271例男性,评估IsoPSA™检测高级别前列腺癌(Gleason≥7)的判别能力。结果显示该检测AUC为0.784,优于总前列腺特异性抗原及游离/总前列腺特异性抗原比值;若活检1000例,可减少不必要活检从705例至402例(43%),仅漏诊22例高级别癌。

要点

  • IsoPSA™检测高级别前列腺癌的AUC为0.784,优于总PSA和游离/总PSA比值。
  • 模拟1000例活检,可减少不必要活检从705例至402例(43%),漏诊22例高级别癌。
  • 多参数磁共振-超声引导活检亚组分析中,AUC提升至0.831。

核心结论

  • 基于结构的IsoPSA检测验证结果与既往报道统计学一致,且性能优于基于浓度的总PSA及游离/总PSA比值。
  • 使用多参数磁共振-超声引导活检时,该检测检出高级别前列腺癌的性能提升可能有助于定义新的诊断范式。

研究设计与样本

  • 多中心前瞻性验证研究,纳入2017年5月至2018年3月在7个学术与社区中心计划接受前列腺活检的271例男性。
  • 活检前采集血样进行IsoPSA检测,以ROC分析评估其检测高级别前列腺癌(Gleason≥7)的判别能力,并与既往结果比较。

主要发现

  • IsoPSA检测高级别癌 vs 低级别癌/良性组织的AUC为0.784,优于总PSA和游离/总PSA比值的AUC。
  • 模拟1000例活检,该检测可将不必要活检从705例降至402例(减少43%),仅漏诊22例高级别癌,其中7例为Gleason评分4+3或更高。
  • 多参数磁共振引导活检亚组分析中,AUC显著提升至0.831。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Current prostate specific antigen markers to detect prostate cancer are limited by low specificity for high grade disease. IsoPSA™ is a blood based, structure focused assay which predicts risk by partitioning the isoforms of prostate specific antigen that are linked to cancer in an aqueous 2-phase reagent system. We validated the clinical performance of this assay for identifying high grade disease in a new contemporary biopsy cohort. MATERIALS AND METHODS: We performed a multicenter prospective validation in 271 men scheduled for prostate biopsy at a total of 7 academic and community centers who were enrolled between May 2017 and March 2018. Blood samples were obtained for assay prior to biopsy. The discrimination power of the assay to detect high grade prostate cancer (Gleason 7 or greater) was evaluated by ROC analysis and compared to prior results. Clinical performance was further improved by comparison with multiparametric magnetic resonance imaging-ultrasound vs transrectal ultrasound guided biopsies. RESULTS: The assay AUC was 0.784 for high grade vs low grade cancer/benign histology, which was superior to the AUCs of total prostate specific antigen and percent free prostate specific antigen. If 1,000 patients were biopsied, the assay would have reduced the number of unnecessary biopsies from 705 to 402 (43%) with only 22 missed high grade cancers, of which 7 would have been Gleason sum 4 + 3 or higher. Subset analysis of multiparametric magnetic resonance imaging guided biopsy produced a substantial improvement of the AUC to 0.831. CONCLUSIONS: Validation of the structure based IsoPSA assay demonstrated statistical concordance with previously reported results and verified its superior performance vs concentration based prostate specific antigen and the free-to-total prostate specific antigen ratio. The assay improvement in detecting high grade prostate cancer using multiparametric magnetic resonance imaging-ultrasound guided biopsy may help define a new diagnostic paradigm.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Stovsky M, Klein EA, Chait A, et al. Clinical Validation of IsoPSA™, a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer. J Urol. 2019. PMID: 30810464. doi:10.1097/JU.0000000000000185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。